Skye Bioscience (SKYE) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Initiated Coverage | Buy | $20.00 | Sep 30, 2025 |
| Evercore ISI Group | Initiated Coverage | Outperform | $10.00 | Aug 15, 2025 |
| JMP Securities | Maintained | Market Outperform | $15.00 | Jun 24, 2025 |
| Citizens Capital Markets | Maintained | Market Outperform | $15.00 | Mar 21, 2025 |
| Craig-Hallum | Maintained | Buy | $14.00 from $18.00 | Mar 21, 2025 |
| William Blair | Initiated Coverage | Outperform | — | Feb 28, 2025 |
| Scotiabank | Initiated Coverage | Sector Outperform | $20.00 | Sep 30, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $14.00 | Sep 20, 2024 |
| Piper Sandler | Maintained | Overweight | $20.00 | Sep 20, 2024 |
| JMP Securities | Initiated Coverage | Market Outperform | $15.00 | Sep 10, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $14.00 | Sep 9, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $14.00 | Sep 6, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $14.00 | Aug 27, 2024 |
| Craig-Hallum | Initiated Coverage | Buy | $18.00 | Jul 9, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $14.00 | Jul 1, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $14.00 | Jun 18, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $14.00 | Jun 17, 2024 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $21.00 | May 23, 2024 |
| Oppenheimer | Initiated Coverage | Outperform | $25.00 | Apr 12, 2024 |
Frequently asked questions
Is SKYE a buy, sell, or hold?
Analysts covering Skye Bioscience currently average a Buy rating: 4 buy, 2 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on SKYE?
On Sep 30, 2025, HC Wainwright & Co. initiated coverage of Skye Bioscience at Buy with a price target of $20.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.